Wednesday, July 8, 2026

Patent intelligence · US

US 12006517

Method for purification of bacteriophage particles

granted A61KA61K35/76A61PA61P31/04
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 18
Applicant portfolio 12
Patent details — US 12006517

Quick answer

US 12006517 (Method for purification of bacteriophage particles) is held by Adaptive Phage Therapeutics, Inc.. Status: granted. Granted Jun 11, 2024. Expires Jun 6, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
19
CPC classes
A61K, A61K35/76, A61P, A61P31/04

More from Adaptive Phage Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12264187

    Compositions and methods for targeted therapeutic delivery to bone

    Theradaptive, Inc. · Expires Mar 27, 2045

    granted
  2. US 12263179

    Lyme disease-associated T cell receptor-related methods

    Adaptive Biotechnologies Corporation · Expires Mar 27, 2045

    granted
  3. US 12266425

    T cell receptor sequences diagnostic for COVID-19 and related compositions

    Adaptive Biotechnologies Corporation · Expires Mar 27, 2045

    granted
  4. US 11911345

    Phage dispensing system

    Adaptive Phage Therapeutics, Inc. · Expires Feb 22, 2044

    granted
  5. US 11773138

    Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof

    Theradaptive, Inc. · Expires Sep 28, 2043

    granted
  6. US 11390921

    Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)

    Adaptive Biotechnologies Corporation · Expires Jul 14, 2042

    granted
  7. US 11192923

    Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof

    Theradaptive, Inc. · Expires Dec 2, 2041

    granted

Frequently asked questions

What is US patent 12006517?

US 12006517 (Method for purification of bacteriophage particles) is held by Adaptive Phage Therapeutics, Inc.. Status: granted. Granted Jun 11, 2024. Expires Jun 6, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12006517?

Adaptive Phage Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.

When does US 12006517 expire?

Our index shows an expiration date of Jun 6, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.